Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acupuncture in Multidisciplinary Treatment for Post-COVID-19 Syndrome.

Medical acupuncture·2022
Same author

Performance of the Universal Vital Assessment (UVA) mortality risk score in hospitalized adults with infection in Rwanda: A retrospective external validation study.

PloS one·2022
Same author

Epidemiology and Outcome of Sepsis in Adults and Children in a Rural, Sub-Sahara African Setting.

Critical care explorations·2021
Same author

Carotid Atheroinflammation Is Associated With Cerebral Small Vessel Disease Severity.

Frontiers in neurology·2021
Same author

A Coronavirus Disease 2019 Pandemic Pivot: Development of the American Board of Anesthesiology's Virtual APPLIED Examination.

Anesthesia and analgesia·2021
Same author

Study on the association of wall shear stress and vessel structural stress with atherosclerosis: An experimental animal study.

Atherosclerosis·2021
Same journal

Critical Care and Contagion: Evolving Frontiers of Infectious Diseases in the Modern Intensive Care Unit.

Critical care clinics·2026
Same journal

Advances and Challenges in Sepsis Care in Low-Resource Settings.

Critical care clinics·2026
Same journal

The Respiratory Triple Pandemic in the Intensive Care Unit: Epidemiology, Clinical Features and Management of COVID-19, Influenza and Respiratory Syncytial Virus.

Critical care clinics·2026
Same journal

Antibiotic Stewardship for the Intensivist.

Critical care clinics·2026
Same journal

Infection Prevention and Control in the Intensive Care Unit.

Critical care clinics·2026
Same journal

Antibiotic Considerations in the Critically Ill: Empiric Choices and Dosing.

Critical care clinics·2026
See all related articles

Related Experiment Video

Updated: Jun 19, 2026

A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

Genetic polymorphisms in sepsis.

Allen Namath1, Andrew J Patterson

  • 1Division of Pulmonary and Critical Care Medicine, Santa Clara Valley Medical Center, San Jose, CA 95128, USA.

Critical Care Clinics
|November 7, 2009
PubMed
Summary
This summary is machine-generated.

Recent advances in genetic polymorphisms offer new ways to identify sepsis patients early. Understanding these genetic variations can lead to more effective interventions for sepsis.

Related Experiment Videos

Last Updated: Jun 19, 2026

A Data-Driven Approach to Quantifying Immune States in Sepsis
07:42

A Data-Driven Approach to Quantifying Immune States in Sepsis

Published on: February 7, 2025

Area of Science:

  • Genetics
  • Immunology
  • Critical Care Medicine

Background:

  • Sepsis remains a leading cause of mortality, necessitating improved diagnostic and therapeutic strategies.
  • Genetic variations, or polymorphisms, influence individual susceptibility and response to sepsis.
  • Identifying genetic markers can aid in early detection and personalized treatment of sepsis.

Purpose of the Study:

  • To summarize recent scientific advances in genetic polymorphisms related to sepsis over the past five years.
  • To highlight discoveries that may improve the early identification of vulnerable sepsis patients.
  • To discuss the implications of genetic research for sepsis management and intervention.

Main Methods:

  • Review of scientific literature focusing on genetic polymorphisms and sepsis from the last five years.
  • Discussion of different study designs, including candidate gene and genome-wide association studies (GWAS).
  • Examination of specific polymorphisms (e.g., E-selectin, apolipoprotein E, C-reactive protein) and their association with sepsis.

Main Results:

  • Several genetic polymorphisms have been identified that are associated with sepsis susceptibility and outcomes.
  • Advances in genomic technologies and large-scale consortia are accelerating sepsis research.
  • Specific gene polymorphisms, such as those in E-selectin, apolipoprotein E, and C-reactive protein, show significant associations with sepsis.

Conclusions:

  • Genetic polymorphism research holds significant promise for improving early sepsis detection and patient stratification.
  • Future advancements in genomics and collaborative research efforts are expected to further refine our understanding and management of sepsis.
  • Ethical and social considerations are important in the context of human genomic studies for sepsis.